Minerva shares rise 20.94% intraday after announcing $200M financing to advance Roluperidone for schizophrenia.

Minerva Neurosciences (NERV) surged 20.94% intraday following the announcement of a $200 million financing to advance its schizophrenia drug Roluperidone. The funding, disclosed on August 23, aims to support clinical development and regulatory submissions for the treatment of negative symptoms in schizophrenia patients. This move signals strong investor confidence in the company’s pipeline progress and financial stability, contrasting with earlier setbacks such as the December 2022 FDA rejection. Prior updates, including a $20 million private placement in June and FDA NDA confirmation in May, had also fueled optimism, but the latest capital raise directly addressed near-term development needs, aligning with the stock’s sharp intraday rally. Unrelated news about a WWII veteran in Ohio and a football match in India had no material impact on the stock’s movement.